SP1 and cancer: We previously reported that an oncolytic adenovirus replicating under the control of mTERT containing an additional c-Myc-binding site and Sp1 sites has a potent and cancer-specific anti-tumour effect that is superior to that mediated by a wild-type hTERT promoter-driven oncolytic adenovirus18.